Anna Анна Smirnova

Dr. Anna Анна Smirnova

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LZLudmila Stepanovna Zubarovskaya
Ludmila Stepanovna Zubarovskaya
IMIvan Moiseev
Ivan Moiseev
MVMaria Dmidrievna Vladovskaya
Maria Dmidrievna Vladovskaya
NMNatalia Mikhailova
Natalia Mikhailova
EMElena Vladislavovna Morozova
Elena Vladislavovna Morozova
AKAlexander Kulagin
Alexander Kulagin
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).

1 July 2013 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
ASAnna Анна Smirnova
Anna Анна Smirnova
SBS. N. Bondarenko
S. N. Bondarenko
AKA. A. Kisina
A. A. Kisina
ASA. V. Smirnov
A. V. Smirnov
ATA. Tsander
A. Tsander
BAB. V. Afanasyev
B. V. Afanasyev
AL amyloidosis is a relatively rare condition belonging to plasma cell dyscrasias with very heterogeneous clinical presentation and poor prognosis. This article presents a brief description of AL amyloidosis, current therapies, and our own statistics on new combination therapy outcomes. We included 46 patients with confirmed AL amyloidosis who received autologous stem cell transplantation and standard combination chemotherapy, including melphalan + dexamethasone or bortezomib + dexamethasone.

28 June 2019 in Cellular Therapy and Transplantation
Verified
Journal Article
Closed access
ASAnna Анна Smirnova
Anna Анна Smirnova
SBSergey N. Bondarenko
Sergey N. Bondarenko
IMIvan S. Moiseev
Ivan S. Moiseev
IMInna V. Markova
Inna V. Markova
EDElena I. Darskaya
Elena I. Darskaya
BABoris V. Afanasyev
Boris V. Afanasyev